imm01

Atherosclerotic Cardiovascular Disease

Phase 2/3Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 89/ 100

Competitive context

16 Active assets in the Atherosclerotic Cardiovascular Disease cohort.

Asset / Sponsor	Phase	Rating
Eicosapentaenoic Acid Ethyl Ester Kobe University	Phase 4	BB
Tirzepatide Brigham and Women's Hospital	Phase 4	BB
UMBELLATINE China National Center for Cardiovascular Diseases	Phase 4	BB
Orforglipron Eli Lilly and Company	Phase 3	B
Inclisiran Novartis Pharmaceuticals	Phase 3	B

View all 17 →

Same molecule, other indications

imm01 is also rated in:

classic Hodgkin lymphomaDormant

B

Indicative ·

62 / 100

myelodysplastic syndromeDormant

CC

Indicative ·

41 / 100

acute myeloid leukemiaDormant

CC

Indicative ·

40 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.